Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fostamatinib - Rigel Pharmaceuticals

Drug Profile

Fostamatinib - Rigel Pharmaceuticals

Alternative Names: FosD; Fostamatinib disodium; Fostamatinib disodium hexahydrate; Fostamatinib sodium; R 985788; R-406/788; R-788; R-935/788; R788 sodium; R935788 sodium; Tamatinib fosdium; Tavalisse; TAVLESSE

Latest Information Update: 30 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer AstraZeneca; Duke University Medical Center; Grifols; Kissei Pharmaceutical; National Heart, Lung and Blood Institute; Rigel Pharmaceuticals; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Vanderbilt University Medical Center
  • Class Anti-inflammatories; Antianaemics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Oxazines; Phosphoric acid esters; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura; Autoimmune haemolytic anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic thrombocytopenic purpura
  • Preregistration COVID 2019 infections
  • Phase III Autoimmune haemolytic anaemia
  • Phase II/III COVID-19 pneumonia
  • Research Waldenstrom's macroglobulinaemia
  • No development reported Graft-versus-host disease; Ovarian cancer
  • Discontinued Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; IgA nephropathy; Rheumatoid arthritis; Solid tumours; Systemic lupus erythematosus; T-cell lymphoma; Type 1 diabetes mellitus

Most Recent Events

  • 28 Sep 2021 Launched for Idiopathic thrombocytopenic purpura (Treatment-experienced) in France, Italy and Spain (PO)
  • 28 Sep 2021 Grifols plans to launch fostamatinib in Czech Republic and in Nordic countries
  • 10 Sep 2021 Biomarkers information updated
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top